Enanta Pharmaceuticals (NASDAQ:ENTA) Rating Increased to Hold at Wall Street Zen

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Sunday.

Separately, JMP Securities upped their price target on shares of Enanta Pharmaceuticals from $23.00 to $24.00 and gave the stock a "market outperform" rating in a research note on Tuesday, June 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $18.00.

Enanta Pharmaceuticals Stock Down 0.7%

Enanta Pharmaceuticals stock opened at $7.18 on Friday. Enanta Pharmaceuticals has a twelve month low of $4.09 and a twelve month high of $17.24. The company has a market capitalization of $153.49 million, a P/E ratio of -1.58 and a beta of 0.76. The stock's 50 day moving average is $6.07 and its 200 day moving average is $6.08.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative return on equity of 79.83% and a negative net margin of 149.57%. The company had revenue of $14.93 million during the quarter, compared to the consensus estimate of $15.96 million. As a group, equities analysts expect that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AlphaQuest LLC raised its stake in shares of Enanta Pharmaceuticals by 16.4% in the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock worth $128,000 after purchasing an additional 3,137 shares during the last quarter. Thrivent Financial for Lutherans bought a new stake in Enanta Pharmaceuticals in the 4th quarter worth about $254,000. Intech Investment Management LLC bought a new stake in Enanta Pharmaceuticals in the 4th quarter worth about $58,000. American Century Companies Inc. raised its position in Enanta Pharmaceuticals by 10.5% in the 4th quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company's stock worth $213,000 after buying an additional 3,501 shares during the last quarter. Finally, Norges Bank bought a new position in Enanta Pharmaceuticals during the 4th quarter valued at about $234,000. 94.99% of the stock is owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.